Round Table Pizza Brings Legendary Flavor to Austin Area

(NASDAQ:FAT), West Coast-Born Pizza Franchise Continues Expansion in Texas with Round Rock, TX Opening LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc., parent company of Round Table Pizza and 17 other restaurant concepts, has announced the opening of its first Round Table Pizza in the Greater Austin area in […]

CTS Corporation Declares a Dividend and Share Repurchase Program

(NYSE:CTS), LISLE, Ill., Nov. 07, 2025 (GLOBE NEWSWIRE) — The Board of Directors of CTS Corporation (NYSE: CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on January 23, 2026, to shareholders of record at the close of business on December 26,

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

(NASDAQ:ELTX), SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activation Robust immune responses were elicited across

Werewolf Therapeutics Presents Data Expanding Its PREDATOR(R) Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

(NASDAQ:HOWL), Novel INDUCER(TM) T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE(TM) molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics,

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

(NasdaqGM:NRIX), SAN FRANCISCO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies to treat cancer and immune disorders, today announced the presentation of new translational data from its ongoing Phase 1 study of NX-1607, an oral, first-in-class inhibitor of Casitas B-lineage lymphoma proto-oncogene B

NextNRG Reports Preliminary October 2025 Revenue Growth of 196% Year-Over-Year

(NASDAQ:NXXT), MIAMI, FL, Nov. 07, 2025 (GLOBE NEWSWIRE) — NextNRG, Inc. (NASDAQ:NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced preliminary unaudited financial results for October 2025. October 2025 Highlights: Revenue: $7.39 million, up 196% year-over-year from $2.50 million in October 2024 Year-to-date revenue through October reached

EQ Appoints Nicholas Nichols as Executive Vice President of Mutual Funds

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — Equiniti (EQ), a leading provider of transfer agent and share ownership services, has named Nicholas (Nick) Nichols as Executive Vice President of the Mutual Funds team. In this role, Nichols will help drive key initiatives across EQ's mutual fund services, driving innovation and service for EQ's valued

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

(NASDAQ:BCAB), — Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents — Mec-V safety profile as monotherapy, and in combination with anti-PD-1 antibody, was manageable and consistent with conditional binding of the AXL target restricted to the tumor microenvironment

T-knife Therapeutics Presents Preclinical Data on PRAME-Targeted TK-6302 Highlighting its Potential as a Promising, Category-leading Therapy at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

— Comprehensive TK-6302 data demonstrate preclinical efficacy and safety, supporting clinical readiness, alongside established scalable manufacturing –TK-6302 Clinical Trial Application planned in Q4 2025 for initiation of the Phase 1 ATLAS trial in 2026 SAN FRANCISCO and BERLIN, Nov. 07, 2025 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR)

Scroll to Top